Want to see TYRA full AI Analyst Report?
Top Page
Tyra Bioscience
(NASDAQ:TYRA)
Select Model
Select Model
Rating:52Neutral
Price Target:
$33.00
▲(7.74% Upside)
Action:Reiterated
Date:08/05/26
TYRA’s score is held back primarily by weak financial performance—no revenue, widening losses, and worsening cash burn—despite the benefit of very low leverage and a sizable equity base. Technicals are moderately supportive with neutral-to-positive momentum and the price holding above key moving averages, while valuation is hard to anchor due to negative earnings and no dividend yield. A small positive governance signal comes from the recent shareholder vote, but it has limited impact versus the company’s burn rate and profitability outlook.
Positive Factors
Balance sheet strength
Extremely low debt and sizable equity provide structural financial flexibility across clinical programs. Low leverage reduces insolvency risk, supports continued R&D spending without near-term covenant pressure, and gives management options (partnering, opportunistic deals) to finance milestones.
Negative Factors
Pre-revenue profile
Being pre-revenue with large and growing net losses means the company has no operating cash generation to fund operations. Long-term value hinges on successful trials and approvals; until then, progress is financed externally, making outcomes binary and execution-risk sensitive.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Extremely low debt and sizable equity provide structural financial flexibility across clinical programs. Low leverage reduces insolvency risk, supports continued R&D spending without near-term covenant pressure, and gives management options (partnering, opportunistic deals) to finance milestones.
Read all positive factors
Tyra Bioscience (TYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.90B
Dividend YieldN/A
Average Volume (3M)370.94K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS Growth-33.07%
CountryUS
Employees87
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding59,470,383
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$49.63Price Target Upside62.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Tyra Bioscience Business Overview & Revenue Model
Company Description
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fi...
How the Company Makes Money
Tyra Biosciences does not currently sell approved products; as a clinical-stage biotech, it has historically funded operations primarily through external financing rather than recurring commercial revenue. The company’s potential ways to generate ...
Tyra Bioscience Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -148.03M | -119.40M | -85.96M | -68.78M | -55.03M | -26.15M |
| Net Income | -148.56M | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
Balance Sheet | ||||||
| Total Assets | 383.36M | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M |
| Cash, Cash Equivalents and Short-Term Investments | 353.94M | 256.00M | 341.44M | 203.47M | 251.21M | 302.18M |
| Total Debt | 5.58M | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M |
| Total Liabilities | 29.70M | 23.43M | 20.41M | 21.59M | 8.35M | 4.96M |
| Stockholders Equity | 353.66M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
Cash Flow | ||||||
| Free Cash Flow | -109.90M | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M |
| Operating Cash Flow | -109.65M | -95.14M | -69.77M | -50.14M | -50.28M | -23.75M |
| Investing Cash Flow | -82.82M | 72.46M | -98.40M | -144.60M | -559.00K | -645.00K |
| Financing Cash Flow | 167.81M | 8.10M | 202.14M | 1.54M | 632.00K | 311.35M |
Tyra Bioscience Risk Analysis
Tyra Bioscience disclosed 87 risk factors in its most recent earnings report. Tyra Bioscience reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tyra Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $2.41B | -6.73 | -76.09% | ― | -58.40% | -31.99% | |
58 Neutral | $1.99B | -33.34 | -47.84% | ― | ― | ― | |
52 Neutral | $1.90B | -14.62 | -42.66% | ― | ― | -33.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $82.86M | -0.21 | 174.85% | ― | -55.42% | -248.85% |
* Healthcare Sector Average
TYRA
Tyra Bioscience
25.71
14.68
133.09%
PVLA
Palvella Therapeutics
154.91
115.84
296.49%
GOSS
Gossamer Bio
0.18
-1.80
-91.06%
NRIX
Nurix Therapeutics
25.12
14.66
140.15%
Tyra Bioscience Corporate Events
Executive/Board ChangesShareholder Meetings
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor
Positive
Jun 2, 2026
At its 2026 Annual Meeting of Stockholders held on May 28, 2026, Tyra Biosciences stockholders elected three Class II directors, Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More, each to serve a three-year term expiring at the 2029 Ann...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.